FDA GLP-1 Approvals Timeline: Every Milestone From Byetta (2005) to Foundayo (2026)
Two decades of GLP-1 history in chronological order — every FDA approval, every label expansion, every discontinuation. From the first short-acting peptide for diabetes through Wegovy MASH, Zepbound OSA, oral Wegovy, and the brand-new Foundayo small-molecule pill, with sources for each entry.
Every GLP-1 receptor agonist on the U.S. market today traces back to a single 2005 approval: Byetta, a synthetic version of a peptide originally found in the saliva of the Gila monster. Two decades later, that single approval has expanded into a class spanning weekly injectables, daily oral pills, dual and triple agonists, and label expansions covering type 2 diabetes, chronic weight management, cardiovascular risk reduction, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis.
This is a chronological record of every major FDA milestone in the GLP-1 class — initial approvals, label expansions, market withdrawals, and the most recent approvals through April 2026. Each entry includes the date, what changed, and a primary source.
The first GLP-1 approvals were modest in clinical effect by today's standards. Their importance was in establishing the drug class — proving that incretin mimetics could safely lower blood sugar in type 2 diabetes — and laying the regulatory and commercial groundwork that semaglutide and tirzepatide would later build on.
FDA approval of exenatide, a synthetic version of exendin-4 (originally identified in Gila monster saliva), as the first glucagon-like peptide-1 receptor agonist for type 2 diabetes. Twice-daily injection. Approved to AstraZeneca (then Amylin/Lilly).
Novo Nordisk's first GLP-1 for type 2 diabetes. Once-daily subcutaneous injection. The longer-acting profile compared to exenatide became the design template for the next generation of GLP-1s.
Once-weekly extended-release formulation of exenatide. The dosing convenience proved transformative for adherence and set the expectation that weekly administration would become the class standard.
GlaxoSmithKline's once-weekly GLP-1 for type 2 diabetes, an albumin-fused peptide. Despite later demonstrating cardiovascular benefit in the HARMONY Outcomes trial (a 22% MACE reduction), Tanzeum failed commercially against Trulicity and Victoza.
Once-weekly subcutaneous injection for type 2 diabetes. Dulaglutide became Lilly's leading GLP-1 product and a major commercial success, foreshadowing the company's later dominance with tirzepatide.
Higher-dose daily liraglutide approved for chronic weight management in adults with obesity, separate from its diabetes indication as Victoza. The first regulatory acknowledgement that GLP-1 receptor agonists had a role in obesity care, not just diabetes.
The arrival of semaglutide changed both the efficacy ceiling and the commercial dynamics of the entire class. Within four years of its first approval, semaglutide moved from a niche diabetes drug to a household name as Wegovy.
Once-weekly semaglutide injection approved for type 2 diabetes. Greater efficacy on both glucose control and weight than any previously approved GLP-1. Set the stage for the obesity reformulation that would follow as Wegovy.
GSK announced it was discontinuing manufacturing and sale of Tanzeum due to limited prescribing and declining sales. Commercial supply was depleted by July 2018. Notably, the discontinuation was for economic, not safety, reasons — and came despite positive cardiovascular outcomes data.
Once-daily oral tablet form of semaglutide approved for type 2 diabetes. The first oral GLP-1 receptor agonist of any kind. Required food-and-water timing protocol, but proved that oral GLP-1 absorption was achievable.
Higher-dose semaglutide injection approved for chronic weight management. The pivotal STEP 1 trial demonstrated mean weight loss of approximately 14.9% over 68 weeks — multiple times any prior obesity medication. Wegovy's launch reframed obesity as a treatable chronic disease.
Tirzepatide's arrival raised the efficacy ceiling further, and both companies began aggressively expanding labels into adjacent indications — adolescents, cardiovascular risk reduction, and the first non-metabolic indication: obstructive sleep apnea.
Eli Lilly's once-weekly tirzepatide injection approved for type 2 diabetes. The first medication to activate both GIP and GLP-1 receptors. Phase 3 SURPASS data showed superior HbA1c and weight reduction compared to existing GLP-1s, presaging the obesity approval that would follow.
Label expansion making semaglutide the first GLP-1 approved for chronic weight management in adolescents aged 12 and older with obesity. Established that the chronic-disease treatment paradigm extended into pediatric obesity care.
Tirzepatide approved as Zepbound for chronic weight management in adults with obesity. SURMOUNT-1 demonstrated up to ~22.5% mean weight loss at 72 weeks at the highest dose — at the time, the largest weight reduction ever seen in a non-bariatric obesity trial.
Label expansion for Wegovy to reduce risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and obesity or overweight. First obesity drug approved for cardiovascular event reduction. Based on SELECT trial (17,604 patients, 20% MACE reduction).
First-ever pharmaceutical treatment approved for obstructive sleep apnea. Zepbound approved for moderate-to-severe OSA in adults with obesity, based on the SURMOUNT-OSA trial showing ~25–29 fewer apnea-hypopnea events per hour vs ~5 with placebo. Created a new insurance-coverage pathway for tirzepatide for patients whose plans don't cover obesity treatment.
The most recent twelve months have produced more FDA milestones than the entire 2010s combined: a MASH indication, an oral weight loss formulation, and the first small-molecule oral GLP-1.
Wegovy 2.4 mg granted accelerated FDA approval for treatment of adults with MASH and moderate-to-advanced liver fibrosis (stages F2–F3), but not cirrhosis. First GLP-1 receptor agonist approved for any liver indication. Based on Part 1 of the Phase 3 ESSENCE trial (800 patients at week 72: 63% achieved MASH resolution vs 34% on placebo). Continued approval contingent on Part 2 outcomes due in 2029.
First oral GLP-1 receptor agonist approved specifically for chronic weight management. Once-daily tablet at 25 mg, based on the OASIS 4 trial (16.6% mean weight loss when treatment was adhered to). Launched January 2026 at $149/month starting dose via NovoCare. Made daily-pill weight loss management a clinical reality.
Eli Lilly's once-daily oral non-peptide GLP-1, approved as Foundayo for chronic weight management. Unlike oral semaglutide, Foundayo can be taken any time of day without food or water restrictions. Notable as the first new molecular entity approved under the FDA's National Priority Voucher Program — issued just 50 days after filing, 294 days before the original PDUFA date of January 20, 2027. The fastest NME approval since 2002. Available via LillyDirect from $149/month self-pay; $25/month with commercial insurance savings card.
What's Pending
Several major regulatory decisions and submissions are expected within the next 12–18 months:
Novo Nordisk submitted the New Drug Application for CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg fixed-dose combination) on December 18, 2025. Standard review timing puts a decision in the second half of 2026. If approved, would be the first once-weekly GLP-1 + amylin analog combination for chronic weight management.
Lilly has stated it plans to submit orforglipron for type 2 diabetes during 2026, separate from its now-approved obesity indication. The five-trial ACHIEVE program is complete except for ACHIEVE-4, which reads out in Q1 2026.
Eli Lilly's Phase 3 SYNERGY-NASH trial of tirzepatide for MASH read out positive results in 2024. A potential second GLP-1-class drug for MASH would create direct competition with Wegovy in the indication.
Lilly's triple agonist (GIP + GLP-1 + glucagon) had its first successful Phase 3 readout in TRIUMPH-4 in December 2025 (28.7% weight loss at the 12 mg dose). Seven additional Phase 3 readouts are expected through 2026, with potential FDA submission to follow.
Amgen's monthly injection (GLP-1 agonist + GIP antagonist conjugate) is in the Phase 3 MARITIME program. If successful, would be the first monthly-dosing obesity medication.
Quick-Look Approval Database
A condensed view of every entry above, organized for quick reference:
| Date | Drug | Action |
|---|---|---|
| Apr 2005 | Byetta (exenatide) | First GLP-1 approved (T2D) |
| Jan 2010 | Victoza (liraglutide) | Daily injection (T2D) |
| Jan 2012 | Bydureon (exenatide ER) | First weekly GLP-1 (T2D) |
| Apr 2014 | Tanzeum (albiglutide) | Approved (T2D) — later discontinued |
| Sep 2014 | Trulicity (dulaglutide) | Weekly injection (T2D) |
| Dec 2014 | Saxenda (liraglutide) | First GLP-1 for chronic weight management |
| Jul 2017 | Tanzeum | Discontinuation announced (depleted Jul 2018) |
| Dec 2017 | Ozempic (semaglutide) | Approved (T2D) |
| Sep 2019 | Rybelsus (oral semaglutide) | First oral GLP-1 (T2D) |
| Jun 2021 | Wegovy (semaglutide) | Approved for chronic weight management |
| May 2022 | Mounjaro (tirzepatide) | First dual GIP/GLP-1 agonist (T2D) |
| Dec 2022 | Wegovy | Approved for adolescents 12+ |
| Nov 2023 | Zepbound (tirzepatide) | Approved for chronic weight management |
| Mar 2024 | Wegovy | CV risk reduction indication |
| Dec 2024 | Zepbound | Approved for OSA + obesity |
| Aug 2025 | Wegovy | Approved for MASH (F2–F3 fibrosis) |
| Dec 2025 | Wegovy pill (oral 25 mg) | First oral GLP-1 for weight loss |
| Apr 2026 | Foundayo (orforglipron) | First oral small-molecule GLP-1 |
Patterns Worth Noting
Acceleration after 2021
From 2005 to 2020, the FDA approved approximately 7 distinct GLP-1 products or formulations. From 2021 through April 2026, it has approved at least 8 — including five major indication expansions and the entirely new oral small-molecule class. The pace is not slowing: at least three additional submissions are pending decision before the end of 2026.
From diabetes to almost everything
The first 16 years of GLP-1 approvals were almost entirely diabetes-focused. The past five have added chronic weight management (2021), adolescent obesity (2022), cardiovascular risk reduction (2024), obstructive sleep apnea (2024), and metabolic liver disease (2025). The next five years will likely add osteoarthritis (TRIUMPH-4 data), kidney disease (FLOW trial), and possibly indications for substance use disorders, depending on trial outcomes.
The class effect for boxed warnings
Every GLP-1 receptor agonist approved in the United States — from the original Bydureon ER through Foundayo — carries the same boxed warning for thyroid C-cell tumors and the same contraindications for personal/family history of medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia type 2 (MEN 2). Detailed coverage of what those warnings mean and who is contraindicated is available in our GLP-1 boxed warning explainer.
Commercial failure can happen
Tanzeum's discontinuation in 2017 — despite eventually demonstrating cardiovascular benefit — is the cautionary tale of the GLP-1 class. Being approved is not enough; clinical performance, prescriber adoption, and pricing competition all matter. The current dominance of semaglutide and tirzepatide reflects efficacy plus commercial execution, not regulatory advantage alone.
While the Pipeline Continues: Current Access
Most of the medications in the timeline above are accessible today through licensed telehealth providers offering both brand-name and compounded options. The fastest path to either Wegovy or Zepbound for most patients is a telehealth platform that bundles consultation, prescription, and pharmacy fulfillment.
Comprehensive GLP-1 weight loss program with full medical intake, prescription, and ongoing clinical oversight. Both semaglutide and tirzepatide programs available.
CPA: $500
Compounded semaglutide and tirzepatide programs with full medical consultation and ongoing provider support.
CPA: $350
Direct care platform that prescribes FDA-approved brand-name GLP-1 medications. Book a consultation with a licensed clinician for either Wegovy or Zepbound.
CPA: $175
The GLP-1 class went from a single twice-daily injection in 2005 to a portfolio spanning weekly injectables, daily oral pills, dual and triple agonists, and indications across diabetes, obesity, cardiovascular disease, sleep apnea, and liver disease in just two decades. The pace of approvals is accelerating — three more major decisions are likely before the end of 2026.
Sources & References
- FDA Press Announcement. FDA Approves First Medication for Obstructive Sleep Apnea. December 20, 2024. fda.gov
- FDA. FDA Approves Treatment for Serious Liver Disease Known as 'MASH'. August 15, 2025. fda.gov
- FDA. NDA 220934 Approval Letter for Foundayo (orforglipron). April 2026. accessdata.fda.gov
- Eli Lilly. FDA approves Lilly's Foundayo (orforglipron). Press release, April 1, 2026. investor.lilly.com
- Novo Nordisk. Wegovy approved by FDA for the treatment of adults with noncirrhotic MASH. Press release, August 15, 2025. prnewswire.com
- Novo Nordisk. FDA approves Wegovy pill, the first oral GLP-1 for weight loss. Press release, December 22, 2025. prnewswire.com
- Novo Nordisk. Wegovy receives FDA approval for cardiovascular risk reduction. Press release, March 8, 2024. prnewswire.com
- Eli Lilly. FDA approves Zepbound for moderate-to-severe OSA in adults with obesity. Press release, December 20, 2024.
- Drugs.com. Albiglutide (Tanzeum): Discontinuation history. drugs.com
- GSK SEC filing. GSK receives US approval for once-weekly type 2 diabetes treatment, Tanzeum (albiglutide). April 15, 2014. sec.gov
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
- Sanyal AJ, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). N Engl J Med. 2025;392:2089-2099.
Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, sourcing standards, or timeline coverage. This article is informational only and does not constitute medical advice.